New drug combo vs. standard for NK/T-cell lymphoma
Part of Cancer clinical trials.
This trial tests if adding a new targeted drug (golidocitinib) to standard chemotherapy plus immunotherapy works better than the standard combo alone for people with advanced or non-nasal NK/T-cell lymphoma that hasn't been treated yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with advanced (stage III or IV) or non-nasal extranodal NK/T-cell lymphoma.
- You haven't had any prior treatment for this lymphoma.
- You are between 18 and 70 years old.
- You are generally healthy enough to be up and about (ECOG score 0 or 1).
- You have at least one tumor that can be measured on scans.
- Your liver and kidney function tests are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (sintilimab, pegaspargase, and GemOx) for people with a type of lymphoma called extranodal NK/T-cell lymphoma (ENKTL) that hasn't been treated before. The goal is to see if this combination helps control the disease.
This trial tests a combination of five drugs to treat a rare blood cancer called NK/T-cell lymphoma that has triggered an abnormal immune response (hemophagocytic lymphohistiocytosis). The goal is to control both the cancer and the harmful immune reaction.
This trial studies whether sugemalimab (or a placebo) added to a chemotherapy plan can better control extranodal NK/T-cell lymphoma that has come back or didn’t respond to previous treatment. It may help patients by improving the chance of shrinking the tumor and extending how long the disease stays under control.
This study tests a new combination of three drugs (Golidocitinib, Pegaspargase, and a PD-1 antibody) as the first treatment for people with a rare type of lymphoma called ENKTL. It aims to see if these drugs together can shrink tumors and improve outcomes.
This trial tests whether a new combination of chemotherapy drugs (P-GEMD) works better than the standard combination (P-Gemox) for people with certain types of natural killer/T-cell lymphoma (a rare blood cancer). It's designed for newly diagnosed or advanced-stage patients who haven't been treated yet.
This trial tests a new drug combined with chemotherapy for patients whose T-cell lymphoma has come back or stopped responding to treatment. The goal is to see if this combination can help shrink tumors and improve outcomes.
Hear when a new Extranodal NK/T-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.